HST-1011 Monotherapy and Combination With Anti-PD1 in Advanced Solid Tumors

Phase 2, open-label trial of HST-1011 in advanced nonhematological malignancy, ovarian cancer, fallopian tube cancer (PFTC) and 6 more (4 arms), sponsored by HotSpot Therapeutics. Primary endpoints: A1: Incidence of dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and safety laboratory/ECG/vital sign/physical exam changes, A2: Integration of safety, pharmacodynamics (PDc), pharmacokinetics (PK), and preliminary efficacy endpoints and 2 more. Started Oct 2023; status: completed.